Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Multiple candidate biomarkers for amyotrophic lateral sclerosis (ALS) have emerged across a range of platforms. Replication of results, however, has been absent in all but a few cases, and the range of control samples has been limited. If progress toward clinical translation is to continue, the specific biomarker needs of ALS, which differ from those of other neurodegenerative disorders, as well as the challenges inherent to longitudinal ALS biomarker cohorts, must be understood. Appropriate application of multimodal approaches, international collaboration, presymptomatic studies, and biomarker integration into future therapeutic trials are among the essential priorities going forward.

Original publication

DOI

10.1002/mus.24470

Type

Journal article

Journal

Muscle Nerve

Publication Date

01/2015

Volume

51

Pages

14 - 18

Keywords

biomarker, motor neuron disease, neurochemistry, neuroimaging, trial, Amyotrophic Lateral Sclerosis, Biomarkers, Humans